- Home
- HRTX vs ECOR Comparison
HRTX vs ECOR Comparison
Compare HRTX & ECOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HRTX | ECOR |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.1M | 81.0M |
| IPO Year | 2007 | 2018 |
Fundamental Metrics
Financial Performance| Metric | HRTX | ECOR |
|---|---|---|
| Price | $0.33 | $9.95 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $4.50 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.7M | 73.6K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $154,904,000.00 | $32,032,000.00 |
| Revenue This Year | $15.28 | $33.60 |
| Revenue Next Year | $20.29 | $30.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 7.36 | ★ 27.20 |
| 52 Week Low | $0.30 | $4.41 |
| 52 Week High | $1.58 | $10.50 |
Technical Indicators
Market Signals| Indicator | HRTX | ECOR |
|---|---|---|
| Relative Strength Index (RSI) | 27.65 | 76.43 |
| Support Level | N/A | $5.70 |
| Resistance Level | $0.46 | $10.13 |
| Average True Range (ATR) | 0.04 | 0.84 |
| MACD | -0.02 | 0.47 |
| Stochastic Oscillator | 11.40 | 89.03 |
Price Performance
Historical ComparisonAbout HRTX Heron Therapeutics Inc.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
About ECOR electroCore Inc.
electroCore Inc is a bioelectronic technology company whose mission is to improve health and quality of life through non-invasive bioelectronic technologies. Its two commercial products are gammaCore non-invasive vagus nerve stimulation, or nVNS, and Quell Fibromyalgia, or Quell. It also sells Truvaga and TAC-STIM products, which are handheld, personal-use consumer products developed to promote general wellness and human performance. It operates in one segment: Bioelectronic Innovations. Geographically, it operates in the United States, the United Kingdom, Japan, and Other.